XNASNAUT
Market cap220mUSD
Jan 10, Last price
1.76USD
1D
-3.30%
1Q
-38.46%
IPO
-83.08%
Name
Nautilus Biotechnology Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
77.02%
Rev. gr., 5y
%
Revenues
0k
Net income
-64m
L-0.10%
CFO
-52m
L+12.89%
Earnings
Jun 13, 2025
Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 81,857 | 67,034 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (81,857) | (67,034) | ||||
NOPBT Margin | ||||||
Operating Taxes | 5,816 | |||||
Tax Rate | ||||||
NOPAT | (81,857) | (72,850) | ||||
Net income | (63,675) -0.10% | (63,740) 26.68% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 632 | 794 | ||||
BB yield | -0.17% | -0.35% | ||||
| Debt | ||||||
Debt current | 7,076 | 1,991 | ||||
Long-term debt | 65,718 | 58,665 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (191,271) | (252,984) | ||||
| Cash flow | ||||||
Cash from operating activities | (51,711) | (45,806) | ||||
CAPEX | (2,442) | (2,324) | ||||
Cash from investing activities | (43,735) | (25,740) | ||||
Cash from financing activities | 368 | 562 | ||||
FCF | (88,513) | (73,556) | ||||
| Balance | ||||||
Cash | 173,418 | 184,471 | ||||
Long term investments | 90,647 | 129,169 | ||||
Excess cash | 264,065 | 313,640 | ||||
Stockholders' equity | (202,481) | (140,406) | ||||
Invested Capital | 506,948 | 485,658 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 124,919 | 124,590 | ||||
Price | 2.99 66.11% | 1.80 -65.25% | ||||
Market cap | 373,508 66.55% | 224,261 -48.74% | ||||
EV | 182,237 | (28,723) | ||||
EBITDA | (76,152) | (63,618) | ||||
EV/EBITDA | 0.45 | |||||
Interest | 5,816 | |||||
Interest/NOPBT | ||||||